the product in the database has an inactive status
indications:
Duodenal ulcer. Stomach ulcer. Moderate and severe reflux oesophagitis. Zollinger-Ellison syndrome and other conditions caused by abnormal, excessive secretion.
Composition:
1 vial contains 40 mg Pantoprazole in the form of a semi-professional sodium salt.
Action:
A drug that inhibits the secretion of hydrochloric acid in the parietal cells of the stomach as a result of selective blocking of H activity+/ K+-ATP-azy (the so-called proton pump). The effect of the drug depends on the dose and leads to the inhibition of both basal secretion and stimulated secretion. It reduces the acidity of gastric contents and, secondarily, in a reversible manner, increases gastrin secretion to an extent proportional to the decrease in acidity. Pantoprazole is approximately 98% bound to plasma proteins. It is metabolized in the liver, excreted in about 80% by the kidneys in the form of metabolites, the remaining part is excreted in the faeces. T0,5 in the elimination phase it is about 1 hour.
Contraindications:
Hypersensitivity to the components of the preparation. Simultaneous treatment with atazanavir.
Precautions:
Intravenous pantoprazole is recommended only in cases where oral administration is not appropriate. The use of pantoprazole is not recommended in mild gastrointestinal disorders, such as nervous indigestion. Diagnosis of reflux oesophagitis should be confirmed endoscopically. Patients with Zollinger-Ellison syndrome or other hypercalcemic acid conditions using long-term treatment with pantoprazole may experience decreased absorption of vitamin VI. B12what is caused by hypochlorhydria or achlorhydria. Due to the lack of data on the use of pantoprazole in children, it should not be administered intravenously to patients in this group.
Pregnancy and lactation:
During pregnancy, use only if absolutely necessary. There are no data on the excretion of pantoprazole in breast milk. If treatment with pantoprazole is necessary, discontinuation of breast-feeding should be considered.
Side effects:
Common: epigastric pain, constipation, bloating, headache. Uncommon: nausea, vomiting, dizziness, blurred vision (blurred vision), hypersensitivity reactions (pruritus, rash). Rare: dryness of the oral mucosa, joint pain. Very rare: leukopenia, thrombocytopenia, thrombophlebitis at the injection site, peripheral edema, severe damage to liver cells (leading to jaundice with or without liver failure), anaphylactic reactions (including anaphylactic shock), muscle pain, depression, interstitial nephritis , urticaria, angioneurotic edema, severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis), hypersensitivity to light, increased transaminases and γ-GT.
Dosage:
Intravenously.Duodenal ulcer disease, gastric ulcer, moderate and severe oesophagitis: 40 mg daily, administered for 2-15 min for up to 1 weekLong-term treatment of Zollinger-Ellison syndrome and other conditions caused by abnormal, excessive secretion: the starting dose is 80 mg per day, then the dose can be increased or decreased depending on the results of the measurement of gastric acid secretion. The daily dose> 80 mg should be given in 2 doses. It is possible to temporarily increase the dose> 160 mg, but it should not be used for longer than required to obtain adequate control of hydrochloric acid excretion. If it is necessary to rapidly reduce acid secretion in the majority of patients, the initial dose is 2 x 80 mg and allows to obtain within 1 h of secretion at the target level of <10 mEq / h. The change of pantoprazole administered intravenously into the oral form should occur as soon as clinically warranted. In patients with impaired renal function and in elderly patients, a daily dose of 40 mg should not be used. In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg. The contents of the vial should be dissolved in 10 ml of 0.9% NaCl.The solution thus prepared may be administered directly or after mixing with 100 ml of 0.9% NaCl solution or 5% Glucose solution. The solution should be used within 12 hours.
(C)
